U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110597) titled 'Communicating Multiple Uncertainties Associated With the Benefits and Risks of New Cancer Drugs' on July 21.
Brief Summary: This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate multiple different sources of uncertainties about the benefits and harms of new cancer drugs on participants' decisions.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Cancer
Intervention:
OTHER: Statement communicating 1 source of uncertainty
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
OTHER: Stateme...